Similar articles for PMID: 28655131

Year	Number of Results
1993	1
1996	1
1997	2
1998	1
1999	3
2000	1
2004	2
2006	1
2007	1
2008	2
2009	1
2010	2
2011	1
2012	1
2014	2
2015	18
2016	9
2017	4
2021	1
2024	0

1

Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Menkiszak J. Cymbaluk-Płoska A, et al. Cancer Biomark. 2017 Jul 19;20(1):31-39. doi: 10.3233/CBM-161546. Cancer Biomark. 2017. PMID: 28655131

2

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.

Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP. Levesque MA, et al. Clin Cancer Res. 2000 Aug;6(8):3260-70. Clin Cancer Res. 2000. PMID: 10955812

3

Prognostic analysis of ovarian cancer patients using the Cox regression model.

Zheng QQ, Wang P, Hui R, Yao AM. Zheng QQ, et al. Ai Zheng. 2009 Feb;28(2):170-2. Epub 2009 Feb 2. Ai Zheng. 2009. PMID: 19550131 Free article.

4

An Analysis of Prognostic Factors in Patients with Ovarian Malignant Germ Cell Tumors Who Are Treated with Fertility-Preserving Surgery.

Yang ZJ, Liu ZC, Wei RJ, Li L. Yang ZJ, et al. Gynecol Obstet Invest. 2016;81(1):1-9. doi: 10.1159/000381771. Epub 2015 May 1. Gynecol Obstet Invest. 2016. PMID: 25967958

5

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P. Juretzka MM, et al. Gynecol Oncol. 2007 Jan;104(1):176-80. doi: 10.1016/j.ygyno.2006.07.027. Epub 2006 Sep 25. Gynecol Oncol. 2007. PMID: 16996584

6

Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.

Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K, Nagata I. Kudoh K, et al. Gynecol Obstet Invest. 1999;47(1):52-7. doi: 10.1159/000010062. Gynecol Obstet Invest. 1999. PMID: 9852392

7

Serum Dickkopf-1 levels as a clinical and prognostic factor in patients with bladder cancer.

Sun DK, Wang L, Wang JM, Zhang P. Sun DK, et al. Genet Mol Res. 2015 Dec 28;14(4):18181-7. doi: 10.4238/2015.December.23.5. Genet Mol Res. 2015. PMID: 26782465 Free article.

8

[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].

Yang ZJ, Wei RJ, Li L. Yang ZJ, et al. Zhonghua Fu Chan Ke Za Zhi. 2012 Dec;47(12):898-904. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 23324188 Chinese.

9

Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.

Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Chambers SK, et al. Clin Cancer Res. 1997 Jun;3(6):999-1007. Clin Cancer Res. 1997. PMID: 9815777

10

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.

Seagle BL, Eng KH, Dandapani M, Yeh JY, Odunsi K, Shahabi S. Seagle BL, et al. Oncotarget. 2015 Jul 30;6(21):18641-52. doi: 10.18632/oncotarget.4080. Oncotarget. 2015. PMID: 26215675 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

51 results

Results by year